Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithm
Reinbolt R, Sonis S, Timmers C, Fernández‐Martínez J, Cernea A, de Andrés‐Galiana E, Hashemi S, Miller K, Pilarski R, Lustberg M. Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithm. Cancer Medicine 2017, 7: 240-253. PMID: 29168353, PMCID: PMC5773952, DOI: 10.1002/cam4.1256.Peer-Reviewed Original ResearchConceptsAromatase inhibitor-related arthralgiaAromatase inhibitorsBreast cancerSystematic chart reviewBreast cancer patientsGenomic risk prediction of aromatase inhibitor-related arthralgias (AIA) in breast cancer (BC) patients using a novel analytical algorithm (NAA).
Reinbolt R, Sonis S, Timmers C, Fernández-Martínez J, deAndrés-Galiana E, Hashemi S, Miller K, Ramaswamy B, Wesolowski R, Noonan A, Dewani S, Williams N, Sardesai S, Pilarski R, Lustberg M. Genomic risk prediction of aromatase inhibitor-related arthralgias (AIA) in breast cancer (BC) patients using a novel analytical algorithm (NAA). Journal Of Clinical Oncology 2017, 35: 10102-10102. DOI: 10.1200/jco.2017.35.15_suppl.10102.Peer-Reviewed Original ResearchAromatase inhibitor-related arthralgiaAromatase inhibitorsSystematic chart reviewBreast cancer patientsCase-control studyPeripheral blood cellsAsymptomatic patientsChart reviewTherapy switchTreatment initiationTreatment complianceBC patientsGenomic risk predictionCancer patientsBreast cancerStage IPatientsClinical phenotypeBlood cellsSNP groupGermline DNACandidate gene studiesStrong association